Skip to main
  1. Stocks
  2. Nurix Therapeutics, Inc
  3. Forecast
NRIX

NRIX Stock Forecast & Price Target

NRIX Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 50%
Buy 43%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Nurix Therapeutics is viewed positively because its lead BTK degrader bexobrutideg is advancing through registrational and combination studies in CLL while also expanding into high-value inflammatory indications, which broadens the addressable market and strengthens the platform thesis. The company’s 3Q26 results showed $673.1 million in revenue, $4.73 in EPS, and $1.1 billion in cash and cash equivalents, indicating strong non-dilutive funding and a runway into 2H29 despite higher one-time Roche-related SG&A. Additional upside comes from a diversified partnered pipeline, including NX-1607, IRAK4, and STAT6, plus collaboration validation from Roche, Gilead, Sanofi, and Pfizer.

Bears say

Nurix Therapeutics is viewed negatively because the downside case hinges on bexobrutideg failing to show competitive durability or raising a safety concern, outcomes that could halt further development and severely impair investor confidence. In that scenario, the stock could migrate toward the company’s net cash position with only minimal pipeline value attributed to its broader platform, underscoring how dependent the valuation is on a single clinical asset. With no evidence in the excerpt of offsetting revenue, diversification, or commercial traction, the company’s single-segment, clinical-stage profile leaves it highly exposed to binary drug-development risk.

NRIX has been analyzed by 14 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 43% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nurix Therapeutics, Inc and is not a guaranteed prediction by Public.com or investment advice.

NRIX Analyst Forecast & Price Prediction

Get the latest NRIX stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in NRIX

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nurix Therapeutics, Inc (NRIX) Forecast

Analysts have given NRIX a Buy based on their latest research and market trends.

According to 14 analysts, NRIX has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $34.36, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $34.36, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nurix Therapeutics, Inc (NRIX)


NRIX Analyst Forecast & Price Prediction

Get the latest NRIX stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in NRIX

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover NRIX stock data and trends